(Q24247962)

29 July 2017

1 reference

title

Thrombolysis for acute ischaemic stroke (English)

1 reference

29 July 2017

1 reference

4

0 references

Joanna Wardlaw

1

object named as

Joanna M Wardlaw

0 references

author name string

Gregory J del Zoppo

2

0 references

Takenori Yamaguchi

3

0 references

J M Wardlaw

1

1 reference

29 July 2017

G Zoppo

2

0 references

T Yamaguchi

3

1 reference

29 July 2017

E Berge

4

0 references

G del Zoppo

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

21 July 2003

0 references

2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

1 reference

29 July 2017

CD000213

1 reference

29 July 2017

3

0 references

2

1 reference

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Evaluation of early computed tomographic findings in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Delayed increase in infarct volume after cerebral ischemia: correlations with thrombolytic treatment and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

European Cooperative Acute Stroke Study (ECASS): (rt-PA-Thrombolysis in acute stroke) study design and progress report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Acute stroke: usefulness of early CT findings before thrombolytic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Hemorrhage after an acute ischemic stroke.MAST-I Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Hypertension and its treatment in the NINDS rt-PA Stroke Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Trials of thrombolysis in acute ischemic stroke: does the choice of primary outcome measure really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Thrombolysis in acute ischemic stroke: does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolysis for acute stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial--Italy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

ECASS II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Trials of streptokinase in severe acute ischaemic stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Termination of trial of streptokinase in severe acute ischaemic stroke. MAST Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolytic therapy for acute ischaemic stroke: promising, perilous, or unproven?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Dissent: an alternative interpretation of MAST-I. Multicentre Acute Stroke Trial--Italy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Multicentre Acute Stroke Trial--Italy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolysis in Acute Stroke Pooling Project: a meta-analysis on individual patient data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolytic therapy with streptokinase in acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolysis for acute ischemic stroke: still a treatment for the few by the few.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Negative interaction of aspirin and streptokinase in acute ischemic stroke: further analysis of the Multicenter Acute Stroke Trial-Italy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Fibrinolytic therapy for acute stroke: the Spanish experience. ECASS-II Spanish Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Brain hemorrhage after thrombolysis: good or bad?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Safety of tissue plasminogen activator for acute stroke in menstruating women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Full heparin anticoagulation should not be used in acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke St

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Reperfusion and metabolic recovery of brain tissue and clinical outcome after ischemic stroke and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Extraparenchymal bleeding predicts an unfavorable outcome in patients with hemorrhagic transformation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

THERAPEUTIC THROMBOLYSIS IN CEREBRAL THROMBOEMBOLISM. DOUBLE-BLIND EVALUATION OF INTRAVENOUS PLASMIN THERAPY IN CAROTID AND MIDDLE CEREBRAL ARTERIAL OCCLUSION

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000213

7 January 2021

10.1002/14651858.CD000213

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2167408

29 July 2017

2167408

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

2167408

1 reference